Fig 1: iPSC-derived macrophage knock-out targeting three macrophage non-essential genes: HPRT1; PPIB and CDK4. (a) Percentage of cell viability (±SEM) in iPSC-derived macrophages 3 days after transduction with pool of 4 sgRNAs of HPRT1, PPIB and CDK4 lentiviruses. CTRL sample are cells after spinfection with PB and Vpx. (b) Fold change (±SEM) of CD14+ and CD11b+ iPSC-derived macrophages 14 days after transduction with HPRT1, PPIB and CDK4 lentiviruses. (c) Western blot analysis of Cas9 protein in CRISPR/Cas9-transduced iPSC-derived macrophages. GAPDH loading control. (d) Detection of HPRT1, PPIB and CDK4 in capillary western blot (Wes) assay in transduced iPSC-derived macrophages (MOI 3). GAPDH loading control. Full length gels and blots are included in Supplementary Figs. S5 and S6. Capillary Wes images were obtained from Compass for SW 5.0.1. software. https://www.proteinsimple.com/compass. n.s. non-significant difference.
Fig 2: P-gp protein expression and maternal BMI in placental tissue. (A) P-gp protein expression in the three maternal BMI groups; normal weight (BMI: 18.5–24.9 kg/m2 (n = 14)), overweight (BMI: 25–29.9 kg/m2 (n = 10)), and obese (BMI ≥ 30 kg/m2 (n = 14)). No statistically significant difference was found (one-way ANOVA, F(2,35) = 1.080, p = 0.351). A p value < 0.05 was considered statistically significant. Each bar represents mean ± SD. (B) Protein expression of P-gp analyzed by linear regression. Each dot represents one sample (n = 38), and line represents best fitted line. Slope = 0.039, F(1,36) = 2.59, R2 = 0.067, p = 0.116. A p value < 0.05 was considered statistically significant. (C) Western blot of P-gp and loading control CYPB, cropped blots. Full blots available in Supplementary Fig. S3–S4.
Fig 3: PPIB independently promotes ERS-induced apoptosis to kill tumor cells.CO co-culture group, CT control group. ***p value < 0.001, ns p value > 0.05. n = 3. A–C Enhanced endoplasmic reticulum tracker MFI in PPIB-treated MDA-MB-231 and BT-549 cells. D Upregulated ERS markers and apoptotic markers in PPIB-treated MDA-MB-231 and BT-549 cells, and ERS-induced apoptosis can be suppressed by ERS inhibitor 4-PBA. E–G Increased proportions of apoptotic MDA-MB-231 and BT-549 cells treated with PPIB, and no increase in apoptosis in cells treated with 4-PBA. H Increased TUNEL-positive stained cells in PPIB-injected MDA-MB-231 xenografts. I Enhanced GDF15 expression in PPIB-injected MDA-MB-231 xenografts. J Upregulated ERS markers and GDF15 were not detected in MDA-MB-231 and BT-549 cells co-cultured with PPIB-knockdown MCF7 cells while reintroducing PPIB into the medium re-activated TAM-induced bystander effect.
Fig 4: PPIB is markedly increased in TAM-treated MCF7 CM.CM conditioned medium, CN control medium. ***p value < 0.001. n = 3. A MCF7 cells were treated with TAM or DMSO to generate serum-free CM or CN, which subsequently underwent label-free quantitative proteomic analysis. Volcano plot of DEPs in MCF7 CM compared to the CN was plotted. B Numbers of upregulated and downregulated DEPs in CM. C Subcellular locations of DEPs. D Heat map visualizing the clustering patterns of DEPs in the CM group and CN group. E GO analysis of the top enriched terms of DEPs. F KEGG enrichment of regulated pathways. G The upregulated MS intensity of PPIB in CM. H, I Increased PPIB RNA levels in MCF7 cells and T47D cells treated with TAM. J, K Increased PPIB levels in CM of MCF7 and PPIB detected by ELISA assays. L, M Increased PPIB levels in both supernatant and cell lysate of MCF7 and T47D cells treated with TAM. N, O Extracellular PPIB levels in MDA-MB-231 and BT-549 cells showed no statistical difference in response to TAM in ELISA assays. P, Q Intracellular and extracellular PPIB levels in TAM-treated MDA-MB-231 and BT-549 cells were not upregulated.
Fig 5: PPIB is the predominant antitumor protein in MCF7 CM.CM conditioned medium, CN control medium. *p value < 0.05, **p value < 0.01, ***p value < 0.001. A Decreased PPIB levels in CM by knocking down PPIB in MCF7 cells. n = 3. B, C CM from MCF7 siPPIB-NC cells repressed the viability of MDA-MB-231 and BT-549 cells. n = 5. D, E CM from MCF7 siPPIB-1 cells showed no repression to the viability of MDA-MB-231 and BT-549 cells. n = 5. F, G CM from MCF7 siPPIB-2 cells showed diminished repression to the viability of MDA-MB-231 and BT-549 cells. n = 5. H, I CM from MCF7 siPPIB-3 cells showed no repression to the viability of MDA-MB-231 and BT-549 cells. n = 5. J, K MDA-MB-231 and BT-549 cells were treated with PPIB at concentrations of 125, 250, and 500 ng/mL. Inhibition of cell viability increased with increasing concentrations. n = 5. L–N Attenuated proliferation was detected in MDA-MB-231 and BT-549 cells treated with 125 ng/mL PPIB. n = 3. O–Q Fewer colonies were formed in PPIB-treated MDA-MB-231 and BT-549 cells. n = 3. R–T PPIB was intratumorally injected daily into MDA-MB-231 xenografts. Reduction in tumor volume and weight was measured. n = 8. U, V Decreased Ki-67 expression was detected in PPIB-injected MDA-MB-231 xenografts. W, X Decreased PCNA expression was detected in PPIB-injected MDA-MB-231 xenografts.
Supplier Page from Abcam for Anti-Cyclophilin B antibody [EPR12703(B)] - Loading Control